About
Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms. Verge Genomics operates in healthcare. Verge Genomics was founded by Alice Zhang. Headquarters: San Francisco, United States.
- Headquarters
- San Francisco, United States
- Founders
- Alice Zhang
- Verified backers
- Not disclosed
- Industry
- Healthcare
Trade on Verge Genomics
Verge Genomics shares
No active listings yet.
Be the first to post →FAQ
Verge Genomics private shares
Practical questions on buying, selling, and pricing Verge Genomics stock in the secondary market.
How to buy Verge Genomics shares?
Verge Genomics is privately held, so there is no public ticker and no exchange order book. Stock typically changes hands when early investors, employees, or funds with existing positions decide to sell, often via a broker or a structured secondary. Transfers are usually subject to the company’s right of first refusal and other restrictions in the stockholders’ agreement. If you are eligible, you can post a buy request on Bubex so holders looking to exit Verge Genomics can find you.
What is Verge Genomics share price?
There is no official Verge Genomics share price. Private names do not print a close. Indicative levels can be inferred from the last priced round, tender offers, and reported secondaries, but those prints are not executable quotes and they often disagree with one another. Cross-check platforms and brokers; the better execution is usually the one you actually get filled at, not the headline mark.
Are Verge Genomics shares publicly traded?
No. Verge Genomics is not listed on NYSE, Nasdaq, or any other public exchange. Any purchase is an off-exchange transfer of existing private stock (or an interest in a vehicle that holds it), not an IPO subscription.
When is the Verge Genomics IPO?
Nobody knows. Verge Genomics has not filed to go public, and private companies do not publish an IPO date in advance. Rumours, banker mandates, and “late 20XX” chatter are not a timetable — many names stay private, get acquired, or slip the listing by years. Until a registration statement is actually filed, treat any IPO date as unknown and use the secondary market if you need access before a listing.
Who can buy Verge Genomics shares on the secondary market?
Secondary access to Verge Genomics is generally limited to accredited investors and other eligible counterparties. Even then, the company or its transfer agent may need to approve the transferee. Bubex introduces buyers and sellers; it is not a broker-dealer and does not execute, custody, or settle the trade.
Can I sell Verge Genomics shares?
Existing holders — typically employees after a vesting event, early investors, or funds — may be able to sell, subject to lock-ups, ROFR, and company policy. If you hold Verge Genomics stock and want liquidity, you can post a sell offer on Bubex to find qualified buyers rather than waiting for a company-run tender.
How is Verge Genomics valued if it is still private?
Private-market value is not a single number. Practitioners look at the last primary round, any 409A, reported tender prices, and implied marks from secondaries. Those inputs can diverge: secondaries often trade at a discount or, less often, a premium to the last round. Bubex surfaces the latest disclosed round and any market indications we can corroborate; treat them as context, not a valuation opinion.
What is the difference between Verge Genomics’s last funding round and a secondary trade?
A funding round is a primary issuance: the company sells new shares and the post-money valuation is reset. A secondary trade is a transfer of shares already outstanding between two holders; it does not recapitalise Verge Genomics the same way. Secondary price per share can therefore sit well away from the last-round mark, which is why you should not treat the headline valuation as your entry price.
Information and introductions only. Bubex does not provide investment advice, brokerage, execution, custody, or settlement. Secondary transfers remain subject to company consents and applicable securities law.